Organization | Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL)

Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL) Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Founded: Soria Spain (1998)

Organization Overview

First Clinical Trial

2018

NCT03410953

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

Active Ingredients

Drugs in Phase 4 Trials (6)

dexamethasone (1 trial)

fendrix vaccine (1 trial)

indocyanine green (ic-green) (1 trial)

levobupivacaine (chirocaine) (1 trial)

methylprednisolone (medrol) (1 trial)

ropivacaine (naropin) (1 trial)

Drugs in Phase 3 Trials (5)

allogeneic mesenchymal stem cells (1 trial)

autologous bone marrow derived mesenchymal cells (1 trial)

hyaluronic acid (1 trial)

quetiapine (seroquel) (1 trial)

semaglutide (Ozempic) (1 trial)

Drugs in Phase 1 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Delirium (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis, Viral, Human (Phase 4)

Stroke (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 12